Chardan Capital Markets launched coverage of NGM Biopharmaceuticals (NASDAQ:NGM) with a “buy” rating and $40 price target. The stock closed at $19.01 on July 6. “We anticipate that NGM’s aldafermin is likely to...
Chardan Capital Markets launched coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and $79 price target. The stock closed at $34.96 on July 6. “We expect that Akero’s lead asset, efruxifermin, has...